Posted by kinasepro on July 14, 2009
… A RAF candidate & Sunesis got a milestone,
In August 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The research term of this collaboration ended in June of 2008. Sunesis retains an option to participate in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration.
Likely derived from WO/2009/006389 & WO/2009/006404
C3=NC=C(C(NC4=CC(C(F)(F)F)=C(Cl)C=C4)=O)S3)=O](http://kinasepro.files.wordpress.com/2009/07/biib-example.jpg?w=344&h=300)
Posted in Biogen, RAF, Sunesis | 2 Comments »
Posted by kinasepro on May 30, 2007
So what is going on with TGF-β anyhow. GSK WO/2002/062794 , Lilly WO/2002/094833, WO/2004/050659, & WO/2005/092894, Biogen WO/2004/072033, and Pfizer (WL) WO/2004/026306 have all been playing in the pyrazole / TGF sandbox but all I’ve seen is some pretty pictures and a few J. Med Chem.’s
Biogen’s got a new one with WO/2007/059359, but not a single mention in during “R&D day.”
Its either supersekrit, or DOA.

Posted in Biogen, Tgf-b | Leave a Comment »